Amarin Corporation

Amarin is a commercial-stage biopharmaceutical company whose mission is to reduce the global burden of cardiovascular disease (CVD). Its primary achievement is the development and commercialization of VASCEPA (icosapent ethyl), which gained a landmark FDA approval for cardiovascular risk reduction based on the pivotal REDUCE-IT outcomes trial. The company's strategy is centered on maximizing the global commercial potential of VASCEPA through geographic expansion, defending its intellectual property, and exploring lifecycle extensions, while its future hinges on navigating generic competition and executing this focused plan.

Amarin's platform is its deep, proprietary expertise in the clinical science and lifecycle management of icosapent ethyl, a purified omega-3 fatty acid (EPA), built upon the landmark REDUCE-IT cardiovascular outcomes trial data.

Amarin faces intense competition from generic icosapent ethyl, other prescription omega-3 therapies, and, increasingly, from newer cardioprotective drug classes like SGLT2 inhibitors and GLP-1 receptor agonists. Its main defense is the unique and robust cardiovascular outcomes data from the REDUCE-IT trial.